Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.60 |
| ▸ | CSF1R | P07333 | 5/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31171317 | 1.00 | CYP11B2 (0.66) | CYP11B2SMN1; SMN2KCNMA1CSF1RCYP11B1 | |
| SCHEMBL31171349 | 0.84 | CSF1R (0.60) | CYP11B2SMN1; SMN2KCNMA1CSF1RCYP11B1 | |
| SCHEMBL31171344 | 0.84 | ROCK2 (0.68) | SMN1; SMN2KCNMA1MEN1KMT2AKDM4E | |
| SCHEMBL31171331 | 0.82 | KMT2A (0.57) | SMN1; SMN2MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL14094289 | 0.80 | JAK2 (0.71) | CYP11B2SMN1; SMN2KCNMA1CSF1RCYP11B1 | |
| SCHEMBL16703342 | 0.79 | CYP11B1 (0.65) | CYP11B2CSF1RCYP11B1MEN1KMT2A | |
| SCHEMBL15058267 | 0.79 | — | — | |
| SCHEMBL1499599 | 0.78 | CYP11B2 (0.71) | CYP11B2KCNMA1CYP11B1MEN1KMT2A | |
| SCHEMBL31171337 | 0.78 | ALDH1A1 (0.48) | SMN1; SMN2MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL30998138 | 0.78 | CYP11B2 (0.77) | CYP11B2SMN1; SMN2KCNMA1CSF1RCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794569-B1 | HETEROCYCLIC UREA COMPOUNDS | BIOTA EUROPE LTD (GB) | 2017-05-10 | — | — | EP | disclosed |
| EP-2794569-B1 | HETEROCYCLIC UREA COMPOUNDS | BIOTA EUROPE LTD (GB) | 2017-05-10 | — | — | EP | disclosed |
| US-9060515-B2 | Heterocyclic urea compounds | BIOTA EUROPE LTD. (GB) | 2015-06-23 | — | — | US | disclosed |
| US-9060515-B2 | Heterocyclic urea compounds | BIOTA EUROPE LTD. (GB) | 2015-06-23 | — | — | US | disclosed |
| US-9060515-B2 | Heterocyclic urea compounds | BIOTA EUROPE LTD. (GB) | 2015-06-23 | — | — | US | disclosed |
| US-20140323486-A1 | HETEROCYCLIC UREA COMPOUNDS | SPERO GYRASE, INC. | 2014-10-30 | — | — | US | disclosed |
| US-20140323486-A1 | HETEROCYCLIC UREA COMPOUNDS | SPERO GYRASE, INC. | 2014-10-30 | — | — | US | disclosed |
| US-20140323486-A1 | HETEROCYCLIC UREA COMPOUNDS | SPERO GYRASE, INC. | 2014-10-30 | — | — | US | disclosed |
| EP-2794569-A1 | HETEROCYCLIC UREA COMPOUNDS | Biota Europe Ltd (GB) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013091011-A1 | HETEROCYCLIC UREA COMPOUNDS | BIOTA EUROPE LTD (GB) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013091011-A1 | HETEROCYCLIC UREA COMPOUNDS | BIOTA EUROPE LTD (GB) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323486-A1 | HETEROCYCLIC UREA COMPOUNDS | UMPS, URB2, UROD | CYP11B2 2508/4885SMN1; SMN2 3938/4885KCNMA1 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.